Sutaida® is approved for listing in China to benefit more patients with neuroendocrine tumors

Sofatinib (Sutaida®) was officially approved by the China National Medical Products Administration ("SFDA") for the treatment of advanced pancreatic neuroendocrine tumors (pNETs)
.

Neuroendocrine tumors originate from cells that interact with the nervous system or glands that produce hormones
.
Neuroendocrine tumors are usually divided into two categories: pancreatic neuroendocrine tumors and non-pancreatic neuroendocrine tumors
.

Previously, Sofatinib was approved in China for the treatment of advanced non-pancreatic neuroendocrine tumors (epNETs)
.
The approval of the State Food and Drug Administration is based on the results of a Chinese Phase III clinical trial study of Sofatinib in patients with advanced pancreatic neuroendocrine tumors
.

  According to the study, the progression-free survival of patients in the sofatinib treatment group was 10.
9 months, and that of patients in the placebo group was 3.
7 months
.
Sofatinib reduces the risk of disease progression or death in patients with advanced pancreatic neuroendocrine tumors by 51%
.
Studies have shown that most patients tolerate the treatment well, and Sofatinib has a controllable safety profile, which is consistent with the observations in previous studies
.

  According to reports, surufatinib is a new type of oral tyrosine kinase inhibitor with dual activities of anti-angiogenesis and immunomodulation
.
He Jun, CEO of He Jun, an innovative biomedical company dedicated to the global development and commercialization of targeted drugs and immunotherapies for the treatment of cancer and immune diseases, told reporters that Sofatinib relies on its unique inhibition of angiogenesis and Promote the dual mechanism of immune response to tumor cells, benefiting patients with non-pancreatic neuroendocrine tumors
.
"With the approval of new indications, we are now able to provide innovative therapies for patients with pancreatic neuroendocrine tumors
.
" (China News Network)